These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26813447)

  • 41. The treatment of masseter hypertrophy with botulinum toxin type A.
    Al-Ahmad HT; Al-Qudah MA
    Saudi Med J; 2006 Mar; 27(3):397-400. PubMed ID: 16532107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidental aggravation of venous malformation after botulinum toxin type a injection for reducing benign masseteric hypertrophy.
    Choi JH; Park SW; Chung HY; Choi KY; Chang HW; Kim JH; Son D; Han K; Cho HC; Xu L; Choi TH; Kim S
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2188-92. PubMed ID: 21134051
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
    Seok J; Koh YG; Hong JK; Yun SH; Kim DH; Son HS; Choi SY; Yoo KH; Lee YW; Kim BJ
    Dermatol Surg; 2024 Jun; 50(6):527-533. PubMed ID: 38518110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment.
    Xie Y; Zhou J; Li H; Cheng C; Herrler T; Li Q
    Plast Reconstr Surg; 2014 Aug; 134(2):209e-218e. PubMed ID: 25068343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of a Novel Botulinum Toxin A for Masseter Reduction: A Randomized, Double-Blind, Placebo-Controlled, Optimal Dose-Finding Study.
    Hong JY; Jeong GJ; Kwon TR; Kim JH; Li K; Kim BJ
    Dermatol Surg; 2021 Jan; 47(1):e5-e9. PubMed ID: 33347002
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy.
    Lee SK
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S105-10. PubMed ID: 17278332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients.
    Lee SH; Wee SH; Kim HJ; Yeo UC; Lee NH; Lee SW; Cho SB
    J Dermatolog Treat; 2013 Apr; 24(2):133-6. PubMed ID: 21888570
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conservative treatment of bilateral temporalis muscle hypertrophy in a pregnant woman.
    Albuquerque CE; Prado R; Pereira-Stabile CL; Filho AM
    J Craniofac Surg; 2012 Jan; 23(1):e20-2. PubMed ID: 22337452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Paradoxical masseteric bulging after botulinum neurotoxin type A injection.
    Sandhu S; Shaefer J
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38749514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle.
    Kim KS; Byun YS; Kim YJ; Kim ST
    Dermatol Surg; 2009 Dec; 35(12):1902-6. PubMed ID: 19737290
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chronic orofacial pain (OFP) of different origin. A case report].
    Rechenberg DK; Kruse A; Grätz KW; Attin T; Lübbers HT
    Schweiz Monatsschr Zahnmed; 2011; 121(9):839-48. PubMed ID: 21987376
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Shim WH; Yoon SH; Park JH; Choi YC; Kim ST
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2161-6. PubMed ID: 21134047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of botulinum toxin type A for the treatment of chronic masticatory myofascial pain: A case series.
    Baker JS; Nolan PJ
    J Am Dent Assoc; 2017 Jan; 148(1):33-39. PubMed ID: 28314397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ultrasonographic Considerations for Safe and Efficient Botulinum Neurotoxin Injection in Masseteric Hypertrophy.
    Lee HJ; Jung SJ; Kim ST; Kim HJ
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33406757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Commentary: The effect of botulinum toxin type A injection on lower facial contouring evaluated using a three-dimensional laser scan.
    Ahn KY
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2167. PubMed ID: 21244566
    [No Abstract]   [Full Text] [Related]  

  • 56. Nonsurgical reshaping of the lower face.
    Liew S; Dart A
    Aesthet Surg J; 2008; 28(3):251-7. PubMed ID: 19083534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lower facial contouring with botulinum toxin type A.
    Tartaro G; Rauso R; Santagata M; Santillo V; Itro A
    J Craniofac Surg; 2008 Nov; 19(6):1613-7. PubMed ID: 19098563
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphatidylcholine/deoxycholate lipolysis and hyaluronic acid augmentation to enhance nonsurgical lower facial contouring using botulinum toxin type A.
    Wong GR; Chen WP
    J Cosmet Dermatol; 2011 Jun; 10(2):159-62. PubMed ID: 21649822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle.
    Kim JH; Shin JH; Kim ST; Kim CY
    Plast Reconstr Surg; 2007 Feb; 119(2):711-7. PubMed ID: 17230111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of botulinum toxin type A in cosmetic facial procedures.
    Jaspers GW; Pijpe J; Jansma J
    Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.